Vickers Venture Partners snags $285m for sixth fund

Its portfolio includes a firm working on a vaccine against COVID-19.

Singapore-based Vickers Venture Partners received commitments amounting to $285.48m (US$200m) for its target $713.69m (US$500m) Fund VI, according to a press release. This excludes general partner commitments.

The company aims it to be the largest non-government linked venture capital fund raised by a VC firm based in Southeast Asia.

Vickers’ portfolio so far comprises companies such as geothermal solutions startup Eavor, medtech decacorn Samumed and bioplastics firm RWDC Industries. It is also funding vaccine company Emergex, which is working on developing vaccinations against COVID-19.

Vickers Venture Partners is a venture capital firm focused on early-stage investments in Asia. The firm’s portfolio covers life sciences, technology, media, and telecommunications as well as consumer and financial services.